I need help with the attached assignment and have included the chapter reading.
I need help with the attached assignment and have included the chapter reading. I appreciate the help.
Saylor URL:http://www.saylor.org/booksSaylor.org180Chapter 6Supporting the Business-Level Strategy: Competitiveand Cooperative MovesLEARNING OBJECTIVESAfter reading this chapter, you should be able to understand and articulate answers to the followingquestions:1.What different competitive moves are commonly used by firms?2.When and how do firms respond to the competitive actions taken by their rivals?3.What moves can firms make to cooperate with other firms and create mutual benefits?Can Merck Stay Healthy?On June 7, 2011, pharmaceutical giant Merck & Company Inc. announced the formation of a strategicalliance with Roche Holding AG, a smaller pharmaceutical firm that is known for excellence in medicaltesting. The firms planned to work together to create tests that could identify cancer patients who mightbenefit from cancer drugs that Merck had under development.[1]This was the second alliance formed between the companies in less than a month. On May 16, 2011, theUS Food and Drug Administration approved a drug called Victrelis that Merck had developed to treathepatitis C. Merck and Roche agreed to promote Victrelis together. This surprised industry expertsbecause Merck and Roche had offered competing treatments for hepatitis C in the past. The Merck/Rochealliance was expected to help Victrelis compete for market share with a new treatment called Incivek thatwas developed by a team of two other pharmaceutical firms: Vertex and Johnson & Johnson.Experts predicted that Victrelis’s wholesale price of $1,100 for a week’s supply could create $1 billion ofannual revenue. This could be an important financial boost to Merck, although the company was alreadyenormous. Merck’s total of $46 billion in sales in 2010 included approximately $5.0 billion in revenuesfrom asthma treatment Singulair, $3.3 billion for two closely related diabetes drugs, $2.1 billion for twoclosely related blood pressure drugs, and $1.1 billion for an HIV/AIDS treatment.
Saylor URL:http://www.saylor.org/booksSaylor.org181Despite these impressive numbers, concerns about Merck had reduced the price of the firm’s stock fromnearly $60 per share at the start of 2008 to about $36 per share by June 2011. A big challenge for Merckis that once the patent on a drug expires, its profits related to that drug plummet because genericdrugmakers can start selling the drug. The patent on Singulair is set to expire in the summer of 2012, forexample, and a sharp decline in the massive revenues that Singulair brings into Merck seemedinevitable.[2]A major step in the growth of Merck was the 2009 acquisition of drugmaker Schering-Plough. By 2011,Merck ranked fifty-third on theFortune500 list of America’s largest companies. Rivals Pfizer (thirty-first)and Johnson & Johnson (fortieth) still remained much bigger than Merck, however. Important questionsalso loomed large. Would the competitive and cooperative moves made by Merck’s executives keep thefirm healthy? Or would expiring patents, fearsome rivals, and other challenges undermine Merck’svitality?Friedrich Jacob Merck had no idea that he was setting the stage for such immense stakes when he tookthe first steps toward the creation of Merck. He purchased a humble pharmacy in Darmstadt, Germany, in1688. In 1827, the venture moved into the creation of drugs when Heinrich Emanuel Merck, a descendantof Friedrich, created a factory in Darmstadt in 1827. The modern version of Merck was incorporated in1891. More than three hundred years after its beginnings, Merck now has approximately ninety-fourthousand employees.
Looking for a Similar Assignment? Order now and Get 10% Discount! Use Coupon Code "Newclient"
